3TC · DIN 02247825 · 300 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
3TC · DIN 02247825
Manufacturer: ViiV Healthcare ULC; listing date 2004-07-20
Health Canada: Marketed since 2013-11-28 · brand 3TC · ATC J05AF05 LAMIVUDINE · form Tablet · route Oral · ingredients LAMIVUDINE 300 MG · company Viiv healthcare ulc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247825)
Source record
DIN 02247825: 3TC
Raw flags: sec3=Y
Item: 081800078; group id 94; item number 0166; lccId None; manufacturer id VIH
Source form: Tab; strength: 300mg
Recorded listing: General benefit
Source prices (unrounded): $13.5060; ministry $5.4857
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247825
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72120
Therapeutic Notes (formulary)
Reimbursement will not be provided for the treatment of hepatitis.
Interchangeable products
Apo-Lamivudine · DIN 02369060 · $5.4857
Jamp Lamivudine · DIN 02507129 · $5.4857
Shortage status: not checked (no credentials)